Apple Beats Earnings Expectations, Roku Shares Surge 6%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 hours ago
0mins
Should l Buy DXCM?
Source: CNBC
- Apple's Strong Earnings: Apple reported fiscal Q2 earnings of $2.01 per share and revenue of $111.18 billion, surpassing analyst expectations of $1.95 and $109.66 billion, although iPhone sales missed estimates for the third consecutive quarter, indicating robust competitiveness in the overall market.
- Roku's Impressive Performance: Roku's Q1 revenue reached $1.25 billion, exceeding the expected $1.20 billion, with adjusted EBITDA of $148.4 million also above the $131.3 million forecast, and the company anticipates continued outperformance in upcoming quarters, highlighting its growth potential in the streaming market.
- Twilio's Strong Rebound: Twilio reported Q1 adjusted earnings of $1.50 per share, beating the $1.27 estimate, with revenue of $1.41 billion also exceeding the $1.34 billion expectation, showcasing sustained growth and strong market demand in the cloud communications sector.
- GoDaddy's Excellent Results: GoDaddy's Q1 earnings were $1.60 per share on revenue of $1.27 billion, both surpassing analyst expectations of $1.52 and $1.26 billion, while free cash flow of $473.6 million exceeded the anticipated $454.2 million, indicating strong competitiveness and profitability in the website building market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DXCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DXCM
Wall Street analysts forecast DXCM stock price to rise
16 Analyst Rating
13 Buy
2 Hold
1 Sell
Strong Buy
Current: 59.550
Low
68.00
Averages
82.54
High
100.00
Current: 59.550
Low
68.00
Averages
82.54
High
100.00
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. It enables people to take control of health through innovative biosensing technology. The G7 is an integrated continuous glucose monitoring system. Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes. The G7 and G7 15 Day includes finger stick elimination, continuous glucose readings and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DEXCOM STOCK RECOVERS IN PREMARKET TRADING, RISING 4.3% FOLLOWING Q1 RESULTS
- Stock Performance: Dexcom shares have seen a reversal in the premarket, increasing by 4.3% following the release of Q1 results.
- Market Reaction: The positive movement in shares indicates investor confidence after the company's quarterly performance report.
See More
Apple, Roku, Estée Lauder Beat Earnings Expectations
- Apple's Strong Earnings: Apple reported a fiscal second-quarter earnings of $2.01 per share and revenue of $111.18 billion, surpassing analyst expectations of $1.95 and $109.66 billion, although iPhone sales missed estimates for the third consecutive quarter, indicating increasing market competition pressures.
- Roku's Robust Growth: Roku's first-quarter revenue reached $1.25 billion, exceeding the expected $1.20 billion, with adjusted EBITDA of $148.4 million also above the forecast of $131.3 million, highlighting the company's ongoing growth potential in the streaming market.
- Estée Lauder's Better-Than-Expected Performance: Estée Lauder reported third-quarter earnings of $0.91 per share and revenue of $3.71 billion, both exceeding analyst estimates, despite announcing job cuts as part of its turnaround strategy, reflecting its adaptive measures in a changing market.
- Moderna's Improved Financials: Moderna posted a first-quarter loss of $3.40 per share, better than the anticipated loss of $4.45, with revenues of $389 million surpassing the $236.4 million estimate, indicating its sustained competitiveness in the vaccine market.
See More
DEXCOM INC: TD COWEN LOWERS TARGET PRICE FROM $84 TO $75
Company Update: DEXCOM has announced a reduction in its target price.
New Target Price: The target price has been cut from $84 to $75.
See More
DexCom Q1 2026 Earnings Call Insights
- Significant Revenue Growth: DexCom reported Q1 2026 revenue of $1.19 billion, reflecting a 15% year-over-year increase, with U.S. revenue at $832 million and international revenue at $360 million, indicating successful market expansion and new product launches.
- Outstanding Product Execution: The launch of the G7 15 Day sensor received positive feedback, with management highlighting the new sensor algorithm's highest accuracy to date, which is expected to drive further market demand and enhance customer satisfaction.
- Improved Profitability: Q1 adjusted EBITDA reached $364.5 million, or 30.6% of revenue, while cash and cash equivalents totaled approximately $2.4 billion, up over $400 million from year-end 2025, showcasing strong cash flow performance.
- Optimistic Outlook: Management reaffirmed full-year revenue guidance of $5.16 billion to $5.25 billion, representing 11% to 13% growth, while also raising non-GAAP operating profit margin and adjusted EBITDA margin guidance, reflecting confidence in future market conditions.
See More
Apple Beats Earnings Expectations, Roku Shares Surge 6%
- Apple's Strong Earnings: Apple reported fiscal Q2 earnings of $2.01 per share and revenue of $111.18 billion, surpassing analyst expectations of $1.95 and $109.66 billion, although iPhone sales missed estimates for the third consecutive quarter, indicating robust competitiveness in the overall market.
- Roku's Impressive Performance: Roku's Q1 revenue reached $1.25 billion, exceeding the expected $1.20 billion, with adjusted EBITDA of $148.4 million also above the $131.3 million forecast, and the company anticipates continued outperformance in upcoming quarters, highlighting its growth potential in the streaming market.
- Twilio's Strong Rebound: Twilio reported Q1 adjusted earnings of $1.50 per share, beating the $1.27 estimate, with revenue of $1.41 billion also exceeding the $1.34 billion expectation, showcasing sustained growth and strong market demand in the cloud communications sector.
- GoDaddy's Excellent Results: GoDaddy's Q1 earnings were $1.60 per share on revenue of $1.27 billion, both surpassing analyst expectations of $1.52 and $1.26 billion, while free cash flow of $473.6 million exceeded the anticipated $454.2 million, indicating strong competitiveness and profitability in the website building market.
See More
Dexcom Reiterates Full-Year Revenue Forecast After Beating Estimates
- Quarterly Performance Beat: Dexcom reported quarterly revenue of $1.19 billion, a 15% year-over-year increase, surpassing analysts' expectations of $1.18 billion, indicating strong demand for its continuous glucose monitors.
- Profitability Improvement: The company posted an adjusted earnings per share of 56 cents, exceeding estimates of 47 cents, reflecting effective strategies in cost control and market demand management.
- Product Innovation and Market Expansion: Dexcom expanded the launch of the Dexcom G7 15-day sensor in the U.S. and added new meal-logging features to the Stelo platform, further solidifying its market position in diabetes care.
- Intensifying Market Competition: With rising awareness of diabetes care and broader insurance coverage, Dexcom faces fierce competition from Medtronic and Abbott, prompting continuous innovation to maintain market share.
See More
DEXCOM STOCK RECOVERS IN PREMARKET TRADING, RISING 4.3% FOLLOWING Q1 RESULTS
- Stock Performance: Dexcom shares have seen a reversal in the premarket, increasing by 4.3% following the release of Q1 results.
- Market Reaction: The positive movement in shares indicates investor confidence after the company's quarterly performance report.
See More
Apple, Roku, Estée Lauder Beat Earnings Expectations
- Apple's Strong Earnings: Apple reported a fiscal second-quarter earnings of $2.01 per share and revenue of $111.18 billion, surpassing analyst expectations of $1.95 and $109.66 billion, although iPhone sales missed estimates for the third consecutive quarter, indicating increasing market competition pressures.
- Roku's Robust Growth: Roku's first-quarter revenue reached $1.25 billion, exceeding the expected $1.20 billion, with adjusted EBITDA of $148.4 million also above the forecast of $131.3 million, highlighting the company's ongoing growth potential in the streaming market.
- Estée Lauder's Better-Than-Expected Performance: Estée Lauder reported third-quarter earnings of $0.91 per share and revenue of $3.71 billion, both exceeding analyst estimates, despite announcing job cuts as part of its turnaround strategy, reflecting its adaptive measures in a changing market.
- Moderna's Improved Financials: Moderna posted a first-quarter loss of $3.40 per share, better than the anticipated loss of $4.45, with revenues of $389 million surpassing the $236.4 million estimate, indicating its sustained competitiveness in the vaccine market.
See More
DEXCOM INC: TD COWEN LOWERS TARGET PRICE FROM $84 TO $75
Company Update: DEXCOM has announced a reduction in its target price.
New Target Price: The target price has been cut from $84 to $75.
See More
DexCom Q1 2026 Earnings Call Insights
- Significant Revenue Growth: DexCom reported Q1 2026 revenue of $1.19 billion, reflecting a 15% year-over-year increase, with U.S. revenue at $832 million and international revenue at $360 million, indicating successful market expansion and new product launches.
- Outstanding Product Execution: The launch of the G7 15 Day sensor received positive feedback, with management highlighting the new sensor algorithm's highest accuracy to date, which is expected to drive further market demand and enhance customer satisfaction.
- Improved Profitability: Q1 adjusted EBITDA reached $364.5 million, or 30.6% of revenue, while cash and cash equivalents totaled approximately $2.4 billion, up over $400 million from year-end 2025, showcasing strong cash flow performance.
- Optimistic Outlook: Management reaffirmed full-year revenue guidance of $5.16 billion to $5.25 billion, representing 11% to 13% growth, while also raising non-GAAP operating profit margin and adjusted EBITDA margin guidance, reflecting confidence in future market conditions.
See More
Apple Beats Earnings Expectations, Roku Shares Surge 6%
- Apple's Strong Earnings: Apple reported fiscal Q2 earnings of $2.01 per share and revenue of $111.18 billion, surpassing analyst expectations of $1.95 and $109.66 billion, although iPhone sales missed estimates for the third consecutive quarter, indicating robust competitiveness in the overall market.
- Roku's Impressive Performance: Roku's Q1 revenue reached $1.25 billion, exceeding the expected $1.20 billion, with adjusted EBITDA of $148.4 million also above the $131.3 million forecast, and the company anticipates continued outperformance in upcoming quarters, highlighting its growth potential in the streaming market.
- Twilio's Strong Rebound: Twilio reported Q1 adjusted earnings of $1.50 per share, beating the $1.27 estimate, with revenue of $1.41 billion also exceeding the $1.34 billion expectation, showcasing sustained growth and strong market demand in the cloud communications sector.
- GoDaddy's Excellent Results: GoDaddy's Q1 earnings were $1.60 per share on revenue of $1.27 billion, both surpassing analyst expectations of $1.52 and $1.26 billion, while free cash flow of $473.6 million exceeded the anticipated $454.2 million, indicating strong competitiveness and profitability in the website building market.
See More
Dexcom Reiterates Full-Year Revenue Forecast After Beating Estimates
- Quarterly Performance Beat: Dexcom reported quarterly revenue of $1.19 billion, a 15% year-over-year increase, surpassing analysts' expectations of $1.18 billion, indicating strong demand for its continuous glucose monitors.
- Profitability Improvement: The company posted an adjusted earnings per share of 56 cents, exceeding estimates of 47 cents, reflecting effective strategies in cost control and market demand management.
- Product Innovation and Market Expansion: Dexcom expanded the launch of the Dexcom G7 15-day sensor in the U.S. and added new meal-logging features to the Stelo platform, further solidifying its market position in diabetes care.
- Intensifying Market Competition: With rising awareness of diabetes care and broader insurance coverage, Dexcom faces fierce competition from Medtronic and Abbott, prompting continuous innovation to maintain market share.
See More
